FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029247037> ?p ?o ?g. }

• W2029247037 abstract "We performed a cost-consequence analysis in a French setting of the renoprotective benefit of irbesartan in hypertensive type 2 diabetes patients over a 25-year period.A previously published Markov model simulated progression from microalbuminuria to overt nephropathy, doubling of serum creatinine, end-stage renal disease and death. Three treatment strategies with analogous blood pressure control were compared: (A) control--conventionally medicated antihypertensive therapy (excluding angiotensin converting enzyme inhibitors, other angiotensin-2-receptor antagonists and dihydropyridine calcium channel blockers) initiated at microalbuminuria; (B) early irbesartan--(300 mg daily added to control, initiated with microalbuminuria) and (C) late irbesartan--(300 mg daily, initiated with overt nephropathy). Probabilities came from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other sources. Clinical and economic outcomes were projected over 25 years. Annual discount rates were 3%.Compared to control, early use of irbesartan added (mean +/- standard deviation) 1.51 +/- 0.08 undiscounted life years (discounted: 0.94 +/- 0.05 years), while late irbesartan added 0.07 +/- 0.01 (0.04 +/- 0.01) years/patient. Early irbesartan added 1.03 +/- 0.06 discounted quality-adjusted life years (QALYs), while late irbesartan added 0.06 +/- 0.01 QALYs. Early and late irbesartan treatments were projected to save 22,314 +/- 1273 euro and 6619 +/- 820 euro/patient, respectively versus control. Sensitivity analysis showed that even over short time horizons both irbesartan treatments were superior to the control group.In France, early irbesartan treatment improved quality and length of life and reduced costs in hypertensive patients with type 2 diabetes and microalbuminuria. Late irbesartan therapy is beneficial, but earlier irbesartan leads to better outcomes." @default.
• W2029247037 created "2016-06-24" @default.
• W2029247037 creator A5007482776 @default.
• W2029247037 creator A5007568068 @default.
• W2029247037 creator A5016312496 @default.
• W2029247037 creator A5037654589 @default.
• W2029247037 creator A5038109838 @default.
• W2029247037 creator A5044496367 @default.
• W2029247037 creator A5045497276 @default.
• W2029247037 creator A5055616921 @default.
• W2029247037 creator A5062936667 @default.
• W2029247037 creator A5065348251 @default.
• W2029247037 creator A5067316228 @default.
• W2029247037 creator A5075068326 @default.
• W2029247037 creator A5084832024 @default.
• W2029247037 creator A5091439412 @default.
• W2029247037 date "2006-09-21" @default.
• W2029247037 modified "2023-10-16" @default.
• W2029247037 title "A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension" @default.
• W2029247037 cites W1606631209 @default.
• W2029247037 cites W1963536918 @default.
• W2029247037 cites W1977371516 @default.
• W2029247037 cites W1986155113 @default.
• W2029247037 cites W1988750822 @default.
• W2029247037 cites W2029604444 @default.
• W2029247037 cites W2044773944 @default.
• W2029247037 cites W2052651539 @default.
• W2029247037 cites W2056976690 @default.
• W2029247037 cites W2068579335 @default.
• W2029247037 cites W2078269768 @default.
• W2029247037 cites W2106979545 @default.
• W2029247037 cites W2169939593 @default.
• W2029247037 cites W2415508123 @default.
• W2029247037 cites W2462717404 @default.
• W2029247037 cites W2522120610 @default.
• W2029247037 cites W62443207 @default.
• W2029247037 cites W95922434 @default.
• W2029247037 cites W2003670762 @default.
• W2029247037 doi "https://doi.org/10.1185/030079906x132730" @default.
• W2029247037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17076969" @default.
• W2029247037 hasPublicationYear "2006" @default.
• W2029247037 type Work @default.
• W2029247037 sameAs 2029247037 @default.
• W2029247037 citedByCount "7" @default.
• W2029247037 countsByYear W20292470372013 @default.
• W2029247037 countsByYear W20292470372014 @default.
• W2029247037 crossrefType "journal-article" @default.
• W2029247037 hasAuthorship W2029247037A5007482776 @default.
• W2029247037 hasAuthorship W2029247037A5007568068 @default.
• W2029247037 hasAuthorship W2029247037A5016312496 @default.
• W2029247037 hasAuthorship W2029247037A5037654589 @default.
• W2029247037 hasAuthorship W2029247037A5038109838 @default.
• W2029247037 hasAuthorship W2029247037A5044496367 @default.
• W2029247037 hasAuthorship W2029247037A5045497276 @default.
• W2029247037 hasAuthorship W2029247037A5055616921 @default.
• W2029247037 hasAuthorship W2029247037A5062936667 @default.
• W2029247037 hasAuthorship W2029247037A5065348251 @default.
• W2029247037 hasAuthorship W2029247037A5067316228 @default.
• W2029247037 hasAuthorship W2029247037A5075068326 @default.
• W2029247037 hasAuthorship W2029247037A5084832024 @default.
• W2029247037 hasAuthorship W2029247037A5091439412 @default.
• W2029247037 hasConcept C126322002 @default.
• W2029247037 hasConcept C126894567 @default.
• W2029247037 hasConcept C134018914 @default.
• W2029247037 hasConcept C2777180221 @default.
• W2029247037 hasConcept C2779922275 @default.
• W2029247037 hasConcept C2780259554 @default.
• W2029247037 hasConcept C2781184683 @default.
• W2029247037 hasConcept C2781203188 @default.
• W2029247037 hasConcept C2781212610 @default.
• W2029247037 hasConcept C519063684 @default.
• W2029247037 hasConcept C555293320 @default.
• W2029247037 hasConcept C71924100 @default.
• W2029247037 hasConcept C84393581 @default.
• W2029247037 hasConceptScore W2029247037C126322002 @default.
• W2029247037 hasConceptScore W2029247037C126894567 @default.
• W2029247037 hasConceptScore W2029247037C134018914 @default.
• W2029247037 hasConceptScore W2029247037C2777180221 @default.
• W2029247037 hasConceptScore W2029247037C2779922275 @default.
• W2029247037 hasConceptScore W2029247037C2780259554 @default.
• W2029247037 hasConceptScore W2029247037C2781184683 @default.
• W2029247037 hasConceptScore W2029247037C2781203188 @default.
• W2029247037 hasConceptScore W2029247037C2781212610 @default.
• W2029247037 hasConceptScore W2029247037C519063684 @default.
• W2029247037 hasConceptScore W2029247037C555293320 @default.
• W2029247037 hasConceptScore W2029247037C71924100 @default.
• W2029247037 hasConceptScore W2029247037C84393581 @default.
• W2029247037 hasLocation W20292470371 @default.
• W2029247037 hasLocation W20292470372 @default.
• W2029247037 hasOpenAccess W2029247037 @default.
• W2029247037 hasPrimaryLocation W20292470371 @default.
• W2029247037 hasRelatedWork W2038657938 @default.
• W2029247037 hasRelatedWork W2039838748 @default.
• W2029247037 hasRelatedWork W2142922621 @default.
• W2029247037 hasRelatedWork W2168763832 @default.
• W2029247037 hasRelatedWork W2353324822 @default.
• W2029247037 hasRelatedWork W2353776243 @default.
• W2029247037 hasRelatedWork W2374699777 @default.
• W2029247037 hasRelatedWork W2376548073 @default.
• W2029247037 hasRelatedWork W2394243274 @default.

• next